Catalysing scale up of rifapentine based TB preventive treatment: progress and challenges
The United Nations high level meeting on TB identified scaling up as a priority. The target has been met for people with HIV but not child contacts and household contacts five years or older. Short course rifapentine based TB preventive treatment is now available as an alternative to six months of isoniazid preventive treatment. The scale up of 3HP (weekly high dose isoniazid and rifapentine) for TB preventive treatment has been catalysed. However, evidence gaps remain that need to be addressed to support scale up of short course TB preventive treatment.
Professor Gavin Churchyard is a physician scientist who is the founder and Group Chief Executive Officer of the Aurum Institute, an independent, not for profit, proudly South African, public benefit organisation that focusses on TB, HIV & COVID19 technical assistance, service delivery, and research. Professor Churchyard is an Honorary Professor at the University of Witwatersrand and adjunct Professor at Vanderbilt University. Professor Churchyard is the principal investigator of the IMPAACT4TB project that aims to catalyse scale up of 3HP in 12 high burden countries and globally. He has extensive clinical trials experience and has conducted numerous TB and HIV trials, including TB preventive treatment trials.